Tags

Type your tag names separated by a space and hit enter

Adapting to a Pandemic - Conducting Oncology Trials during the SARS-CoV-2 Pandemic.
Clin Cancer Res. 2020 Jul 01; 26(13):3100-3103.CC

Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has necessitated changes in cancer care delivery as resources are reallocated. Clinical trials and other research activities are inevitably impacted. Start-up activities for new trials may be deferred and recruitment suspended. For patients already enrolled however, there are challenges in continuing treatment on trial. Regulatory bodies have issued guidance on managing clinical trials during the pandemic, including contingency measures for remote study visits, delivery of investigational product, and site monitoring visits. New cancer clinical trial practices during the SARS-CoV-2 pandemic include new risk assessment strategies, decentralized and remote trial coordination, data collection, and delegation of specific therapeutic activities. This experience could provide evidence of more feasible and cost-effective methods for future clinical trial conduct.

Authors+Show Affiliations

Division of Medical Oncology, National Cancer Centre Singapore, Singapore.Duke University Medical Center, Duke University, Durham, North Carolina.Duke University Medical Center, Duke University, Durham, North Carolina. mustafa.khasraw@duke.edu.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32312892

Citation

Tan, Aaron C., et al. "Adapting to a Pandemic - Conducting Oncology Trials During the SARS-CoV-2 Pandemic." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 26, no. 13, 2020, pp. 3100-3103.
Tan AC, Ashley DM, Khasraw M. Adapting to a Pandemic - Conducting Oncology Trials during the SARS-CoV-2 Pandemic. Clin Cancer Res. 2020;26(13):3100-3103.
Tan, A. C., Ashley, D. M., & Khasraw, M. (2020). Adapting to a Pandemic - Conducting Oncology Trials during the SARS-CoV-2 Pandemic. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 26(13), 3100-3103. https://doi.org/10.1158/1078-0432.CCR-20-1364
Tan AC, Ashley DM, Khasraw M. Adapting to a Pandemic - Conducting Oncology Trials During the SARS-CoV-2 Pandemic. Clin Cancer Res. 2020 Jul 1;26(13):3100-3103. PubMed PMID: 32312892.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adapting to a Pandemic - Conducting Oncology Trials during the SARS-CoV-2 Pandemic. AU - Tan,Aaron C, AU - Ashley,David M, AU - Khasraw,Mustafa, Y1 - 2020/04/20/ PY - 2020/04/13/received PY - 2020/04/15/revised PY - 2020/04/16/accepted PY - 2020/4/22/pubmed PY - 2020/7/14/medline PY - 2020/4/22/entrez SP - 3100 EP - 3103 JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 26 IS - 13 N2 - The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has necessitated changes in cancer care delivery as resources are reallocated. Clinical trials and other research activities are inevitably impacted. Start-up activities for new trials may be deferred and recruitment suspended. For patients already enrolled however, there are challenges in continuing treatment on trial. Regulatory bodies have issued guidance on managing clinical trials during the pandemic, including contingency measures for remote study visits, delivery of investigational product, and site monitoring visits. New cancer clinical trial practices during the SARS-CoV-2 pandemic include new risk assessment strategies, decentralized and remote trial coordination, data collection, and delegation of specific therapeutic activities. This experience could provide evidence of more feasible and cost-effective methods for future clinical trial conduct. SN - 1557-3265 UR - https://www.unboundmedicine.com/medline/citation/32312892/Adapting_to_a_Pandemic___Conducting_Oncology_Trials_during_the_SARS_CoV_2_Pandemic_ DB - PRIME DP - Unbound Medicine ER -